Published Paper Details:

Multiple System Atrophy (MSA) is a rare, rapidly progressive neurodegenerative disorder characterized by various combinations of autonomic dysfunction, parkinsonism, and cerebellar ataxia. While often misdiagnosed as Parkinson's disease (PD) or progressive supranuclear palsy (PSP), MSA follows a more aggressive course with distinctive neuropathology. This study aims to elucidate MSA's clinical heterogeneity and identify key biomarkers and pathological mechanisms underlying its progression. Through a combination of retrospective cohort analysis, cerebrospinal fluid (CSF) biomarker assays, neuroimaging review, and neuropathological examination, we investigate diagnostic accuracy, disease progression, and overlaps with other synucleinopathies. Results demonstrate that MSA patients exhibit distinct CSF ?-synuclein oligomer patterns, greater cerebellar atrophy on MRI, and more rapid autonomic decline compared to matched PD patients. These findings support the hypothesis that MSA represents a distinct alpha-synucleinopathy with unique neurodegenerative trajectories. Limitations include small sample size and retrospective design. We propose future longitudinal and multi-center studies to validate biomarkers and refine disease-modifying therapeutic targets.